Combination of Henagliflozin and Continuous Subcutaneous Insulin Infusion in T2DM

Korábbi kezelés

• Severe chronic gastrointestinal diseases, or those who have received treatment that may affect drug absorption (such as gastrointestinal surgery)

Más betegség

• Urinary tract infection or/and genital infection with clinical significance, or repeated urinary tract infection or/and genital infection history
• People with negligent compensatory heart failure (NYHA grade III and IV), unstable angina, stroke or transient ischemic attack, myocardial infarction, serious arrhythmia, cardiac surgery or vascular reconstruction within 6 months
• Serious blood system disease (such as aplastic anemia, myelodysplastic syndrome) or any disease causing hemolysis or erythrocyte instability (such as malaria, hemolytic anemia)
• Those who have mental or nervous system diseases and are unwilling to communicate or cannot fully understand and cooperate

Laborértékek

• Serious trauma or acute infection occurred within 4 weeks that may affect blood glucose control
• ALT>3.0x ULN and/or AST>3.0x ULN and/or Tbil>2.0x ULN Blood ketone body>ULN eGFR<30ml/min/1.73 m2 Blood creatine kinase>3.0x ULN

Egyéb

• Diabetic ketosis or ketoacidosis, diabetic hypertonic state, diabetic lactic acidosis and other acute diabetic complications or serious chronic diabetic complications
• Uncontrolled hyperthyroidism
• Pregnant or lactating women

• Diagnosed as type 2 diabetes mellitus, diagnosis time ≤ 2 years
• Age between 20 and 70 years
• Continuous use of any hypoglycemic drug ≤ 7 days within 6 months
• 9% ≤ HbA1c ≤ 14% or fasting blood glucose ≥ 11.1 mmol/L
• Body mass index (BMI) of between 20 and 32 kg/m2
• Be able to understand the contents and methods of this study and sign the informed consent form voluntarily